Munger Mode rating: 3 out of 5 — Hold. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
We would keep a share of Eli Lilly if we already owned it. We would not buy one at the price the market is paying this morning. This is the first of the two businesses that land on three stars: a wonderful franchise, run by capable people, selling above what we think the earning power is worth. The moat is real. The price has no margin of safety. The tape is moving. Lilly reported third-quarter results before the open and raised its full-year revenue outlook for the third time this year. The prior close, on October 28, was $1,288.30. In the first hour of trading on October 29 the stock changed hands around $1,390, with prints from roughly $1,330 to above $1,400. Every valuation figure below uses $1,390 and about 891 million shares outstanding. That is a market value of approximately $1.24 trillion. Diluted shares in the quarter were 893.4 million.
Recent filings analysed: 8-K (2026-10-29), 10-Q (2026-10-29), 8-K (2026-08-05), 10-Q (2026-08-05).
Stock screener · Superinvestor 13F holdings · Analyst sentiment